Scientific Technology and R&D

IMM01 + Inetetamab

Inetetamab, independently developed by Sunshine Guojian, is a HER2 monoclonal antibody which was approved by the NMPA in June 2020 for the treatment of HER2-positive metastatic BC in combination with chemotherapy. ImmuneOnco reached a collaboration with Sunshine Guojian, under which Sunshine Guojian will be primarily responsible for driving and funding the clinical development of the combination treatment of IMM01 and inetetamab for HER2-positive solid tumors in mainland China. We have obtained an IND approval for a Phase Ib/II clinical trial in HER2-positive solid tumors from the NMPA in August 2021.